Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340

AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (original) A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

W is nitrogen or CH;

R^1 is selected from hydrogen or fluorine; and

R^y is a C_{1-4} aliphatic group, optionally substituted with $N(R^2)_2$ or a 5-6 membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:

each R^2 is independently selected from hydrogen or a C_{1-3} aliphatic group optionally substituted with OH, $N(R^3)_2$, or a 5-6 membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and wherein:

each R^3 is independently selected from hydrogen or a C_{1-3} aliphatic group;

provided that:

when R^1 is hydrogen and W is CH, then R^y is other than methyl.

2. (original) The compound of claim 1, wherein R^y is a C_{1-4} aliphatic group.

Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340

3. (original) The compound of claim 2, wherein R^y is selected from methyl, ethyl, cyclopropyl, *tert*-butyl, or isopropyl.

4. (original) The compound according to claim 3, wherein R^y is selected from methyl, cyclopropyl, or *tert*-butyl.

5. (original) The compound according to claim 1, wherein W is nitrogen.

6. (original) The compound according to claim 1, wherein W is CH.

7. (original) The compound according to claim 1, wherein R^1 is hydrogen.

8. (original) The compound according to claim 1, wherein R^1 is fluorine.

9. (original) The compound according to claim 1, wherein R^y is a C_{1-4} aliphatic group substituted with a 6-membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

10. (original) The compound according to claim 9, wherein R^y is a C_{1-4} aliphatic group substituted with a morpholinyl, piperidinyl, or piperazinyl ring

11. (original) The compound according to claim 1, wherein R^y is a C_{1-4} aliphatic group substituted with $N(R^2)_2$.

12. (original) A compound selected from the group consisting of:

Applicants: Cornelia J. Forster et al.
Application No.: 10/632,340



I-1



I-2



I-3



I-4



I-5



I-6



I-7



I-8



I-9



I-10



I-11



I-12



I-13



I-14



I-15



I-16



I-17



and I-18.

13. (original) A pharmaceutically acceptable composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvent, or vehicle.

14. (original) The composition according to claim 13, additionally comprising an additional therapeutic agent selected from a treatment for Alzheimer's Disease (AD), a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating stroke, an agent for treating cardiovascular disease, an antidepressant, an anti-psychotic agent, or an agent for treating diabetes.

15. (previously presented) A method of inhibiting GSK3 kinase activity in a biological sample, comprising the step of contacting said biological sample with:

a) a composition according to claim 13; or

b) a compound according to claim 1;

in an amount effective for inhibiting GSK3 kinase activity.

16-17. (canceled)

18. (currently amended) ~~The method according to claim 17, wherein said~~ A method of treating a disease, disorder, or condition [[is]] selected from ~~allergy, asthma,~~ diabetes, ~~Alzheimer's disease, Huntington's disease, Parkinson's disease, AIDS-associated dementia, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), multiple sclerosis (MS), an injury due to head trauma,~~ schizophrenia, anxiety, bipolar disorder, ~~tauopothy, a spinal cord or peripheral nerve injury, myocardial infarction, cardiomyocyte hypertrophy, glaucoma, attention deficit disorder (ADD),~~ depression, ~~a sleep disorder, reperfusion/ischemia,~~ stroke, ~~an angiogenic disorder, or baldness,~~ in a patient in need thereof, comprising administering the composition according to claim 13 to said patient.

19-22. (canceled)

23. (currently amended) The method according to claim [[17]] 18, comprising the additional step of administering to said patient an additional therapeutic agent selected from a ~~treatment for Alzheimer's Disease (AD), a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS), a treatment for asthma, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor,~~ an agent for treating stroke, ~~an agent for treating cardiovascular disease,~~ an antidepressant, an anti-psychotic agent, or an agent for treating diabetes, wherein:

said additional therapeutic agent is appropriate for the disease being treated; and

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.